A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
New Therapeutic Possibilities of Type 2 Diabetes Mellitus Management: Experience of Voglibose Application
Mìžnarodnij Endokrinologìčnij Žurnal
Objective of the study — an estimation of efficiency of application and tolerability of new alpha-glucosidase inhibitor voglibose (Voxid) in the treatment of patients with type 2 diabetes mellitus (DM). Material and Methods. We have examined 20 patients with type 2 DM aged from 32 to 65 years, who did not have satisfactory glycemic control during previous treatment. Before the beginning of research and during all supervision they received previous hypoglycemic therapy (metformin anddoi:10.22141/2224-07220.127.116.114.76937 doaj:d8e2fbf9567445fc80b0074908d035cc fatcat:73ovydfw25e2xkyezav6ctumem